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a  b  s  t  r  a  c  t
Presarcopenia and sarcopenia were evaluated in HIV-infected individuals and in healthy
elderly controls according to the consensus deﬁnitions of the European Working Group on
Sarcopenia in Older People. Bioelectrical impedance, a hydraulic hand dynamometer, and
gait  speed were used to evaluate muscle mass, muscle strength, and physical performance,
respectively. Adjusted and unadjusted binary logistic regression predicted the risk of sar-
copenia. Predictor contribution was assessed by the Wald test. Signiﬁcance was established
at  p ≤ 0.05. The HIV-infected group consisted of 33 patients on treatment (42.4% women;
mean age 59 ± 7 years; mean BMI 25 ± 6 kg/m2; viral load undetectable in 30 cases). The HIV-
uninfected group consisted of 60 individuals (71.7% women; mean age 70 ± 7 years; mean
BMI  28 ± 6 kg/m2). Of the controls, 4 (6.7%) individuals had presarcopenia and 4 (6.7%) sar-
copenia compared to 4 (12.1%) and 8 (24.2%), respectively, in the HIV-infected group. The
HIV-infected patients had a 4.95 higher risk (95% CI: 1.34–18.23) for sarcopenia compared
to  the controls. It should be pointed out that the control group was on average 10 years
older. This risk increased further (RR = 5.20; 95% CI: 1.40–19.20) after adjusting for age andBMI. HIV-infected patients were shown to be at a greater risk of sarcopenia, an indicator of
frailty, even following adjustment for age and BMI.
© 2015 Elsevier Editora Ltda. All rights reserved.he term sarcopenia (sarx meaning ﬂesh and penia poverty)
as ﬁrst proposed by Irwin Rosenberg in 1989 to describe
he decline in muscle mass associated with age.1,2 Currently,
he European Working Group on Sarcopenia in Older People
EWGSOP) has broadened this concept by including muscle
trength and physical performance as additional diagnostic
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.criteria, and proposing the stages presarcopenia, sarcopenia,
and severe sarcopenia.3
Human immunodeﬁciency virus/acquired immunodeﬁ-itoria, ES 29025-023, Brazil.
ciency syndrome (HIV/AIDS) is currently considered a chronic
disease due to the advances made in antiretroviral therapy
(ART) in recent years. As the prevalence of opportunistic
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infections decreased, there was an increase in the preva-
lence of chronic pathologies such as cardiovascular, liver,
and kidney diseases, cognitive disorders, and osteoporosis.4
This fact has generated speculations in relation to a probable
“accelerated aging syndrome” in HIV-infected patients.5 Sev-
eral investigators have demonstrated bone mass loss and a
greater fracture risk in HIV-infected patients.6 Whenever pre-
mature age-related comorbidities are detected in HIV-infected
patients, it is crucial to evaluate the presence of sarcopenia,
an important condition responsible for an increased risk of
falls and fractures that may ultimately lead to immobility and
dependency.7 Indeed, sarcopenia may increase morbidity and
mortality.8
The objective of this cross-sectional, analytical study was
to compare the prevalence of sarcopenia, presarcopenia,
and severe sarcopenia in HIV-infected patients compared to
healthy HIV-uninfected elderly individuals.
The study was conducted at the sexually transmitted infec-
tions/AIDS outpatient clinic and at the geriatric outpatient
clinic of the Santa Casa de Misericórdia, a university teach-
ing hospital in Vitória city, Brazil between December 2013
and July 2014. The sample consisted of HIV-infected individ-
uals of 50 years of age or more  under antiretroviral therapy
(ART) and HIV-uninfected individuals of 60 years of age or
more. Individuals with neurological diseases, chronic pul-
monary disease, partial paralysis, or any other morbidity that
could affect their physical performance were excluded from
the study. The study protocol was approved by the internal
review board of the Escola Superior de Ciências da Saúde da
Santa Casa de Misericórdia de Vitória (EMESCAM) under refer-
ence CAAE: 09180512.9.0000.5065. All participants signed an
informed consent form.
A bioelectrical impedance scale (InBody 520 device;
Biospace Inc., Beverly Hills, CA, USA) was used to evaluate
muscle mass. The reproducibility of this method is good and it
represents an acceptable alternative to the gold standard tests,
magnetic resonance imaging and dual-energy X-ray absorp-
tiometry (DXA).9 Using the Janssen equation, the normalized
skeletal muscle index (SMI) (absolute muscle mass in kilo-
grams/squared height in meters) was calculated. SMI was
deﬁned as low when values were ≤10.75 for men  and ≤6.75
for women.3,10
Muscle strength was evaluated using a Jamar hydraulic
hand dynamometer (Sammons Preston, Bolingbrook, IL, USA).
The arithmetic mean of three measurements taken with
the dominant hand was calculated and then adjusted for
body mass index (BMI).3 Muscle strength was considered
reduced under the following conditions for men: BMI  ≤ 24
and strength ≤ 29 kg; BMI  from 24.1 to 28 and strength ≤ 30 kg;
BMI  > 28 and strength ≤ 32 kg. The parameters for women
were: BMI  ≤ 23 and strength ≤ 17 kg; BMI  from 23.1 to 26 and
Table 1 – Frequency of presarcopenia and sarcopenia in the stu
Normal Presa
HIV-uninfectedn  (%) 52 (86.7%) 4 (6
HIV-infected n (%) 21 (63.6%) 4 (1
Total n (%) 73 (78.5%) 8 (8 0 1 6;2 0(1):99–102
strength ≤ 17.3; BMI from 26.1 to 29 and strength ≤ 18 kg, and
BMI  > 29 and strength ≤ 21 kg.11 These parameters were previ-
ously deﬁned and validated by the European working group
on sarcopenia in older people.12
Physical performance was evaluated according to the gait
speed test in which the patient is asked to walk a distance
of 4 m in a maximum time of 5 s, with performance being
considered impaired when speed is less than 0.8 m/s3.
In accordance with the EWGSOP deﬁnitions, low SMI  as an
isolated ﬁnding characterized presarcopenia. The association
of low SMI with either low muscle strength or poor physical
performance was considered sarcopenia,  while a reduction in
all three criteria was classiﬁed as severe sarcopenia.3
The continuous variables were described as means and
standard deviations, while the dichotomous variables were
described as percentages. Student’s t-test for independent
samples and chi-square test or Fisher’s exact test were used
for group comparison. Binary logistic regression, either unad-
justed or adjusted for age and BMI, was used to predict the
likelihood of association with sarcopenia. The statistical sig-
niﬁcance of the contribution of the predictors in the regression
model was determined using the Wald test. p-values < 0.05
were considered statistically signiﬁcant. The SPSS statistical
software program, version 22.0 was used throughout the anal-
ysis.
The study was conducted over a 6-month period and
included 93 individuals. Of these, 33 were HIV-infected
patients on ART. In 30 (90.9%) of those patients, viral load was
undetectable. In relation to gender, 42.42% were women and
57.58% men. Mean age was 59 ± 7 years (range 50–78 years) and
mean BMI was 25 ± 6 kg/m2 (range 17.7–52.4 kg/m2). Of the 60
HIV-uninfected controls, 71.7% were women and 28.3% men.
Mean age was 70 ± 7 years (range 60–87 years) and mean BMI
was  28 ± 6 kg/m2 (range 15.3–41.6 kg/m2).
Based on the EWGSOP diagnostic criteria for sarcopenia, 52
individuals in the HIV-uninfected control group (86.7%) were
normal, 4 (6.7%) had presarcopenia and 4 (6.7%) had sarcope-
nia. In the HIV-infected group, 21 (63.6%) were normal, while
4 (12.1%) had presarcopenia, and 8 (24.2%) had sarcopenia
(Table 1). Presarcopenia was 3.71 (95% CI: 1.32–10.38) times
more  common in the HIV-infected group in relation to the
control group. After adjusting for age and BMI, this risk ratio
increased to 3.90 (95% CI: 1.38–10.95). The risk of sarcopenia
was 4.95 (95% CI: 1.34–18.23) times higher for HIV-infected
individuals compared to the HIV-uninfected controls. Follow-
ing adjustment for age and BMI, this risk ratio increased to
5.20 (95% CI: 1.40–19.20), as shown in Table 2.
The study group was younger and mostly male reﬂect-
ing the composition of the HIV outpatient clinic whereas
the control group was older and mostly female reﬂecting
the composition of the outpatient geriatric clinic, as those
dy sample.
rcopenia Sarcopenia Total
.7%) 4 (6.7%) 60 (100%)
2.1%) 8 (24.2%) 33 (100%)
.6%) 12 (12.9%) 93 (100%)
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Table 2 – Unadjusted and adjusted binary logistic regression analysis.
Unadjusted p-value Adjusted for age and BMI p-value
Presarcopenia
HIV-uninfected 1 0.01 1 0.01


















































HIV-infected 4.95 (1.34–18.22) 
ndividuals were consecutively recruited for the study pro-
ocol. As sarcopenia is more  common in women than in
en, and in older people than younger, we  should have
xpected greater frequency of sarcopenia in the control
roup but the results have shown the opposite, even after
djustment by multivariate analysis. Unfortunately, as the
ample was small, it was not possible to stratify the differ-
nt groups for gender. The patients in the study group were on
ntiretroviral therapy for 7.15 ± 3.74 years. The main backbone
as Lamivudine–Zidovudine used by 17 patients followed by
amivudine–Tenofovir in 16 patients. The third drug used
as Efavirenz in 13 patients, followed by ritonavir-boosted
tazanavir in 8, ritonavir-boosted lopinavir in 8, nevirapine in
, and ritonavir-boosted darunavir in the remaining 2 patients.
These ﬁndings reveal a strong positive association of pre-
arcopenia and sarcopenia with HIV infection in patients with
 mean age of 59 years and on regular use of ART, most with
n undetectable viral load, compared to an uninfected group
f older individuals with a mean age of 70 ± 7 years of age.
lthough the mean age and gender distribution of patients
hat compose the two outpatient groups were not equiva-
ent, that makes indeed stronger the association between
IV infection and sarcopenia. Yarasheski et al. conducted a
ongitudinal study and reported similar rates of skeletal mus-
le mass loss in an HIV-infected group and in the control
roup; however, those investigators failed to evaluate muscle
trength and function.13
The present frequencies of presarcopenia and sarcope-
ia found for the HIV-infected patients (12.1% and 24.2%,
espectively) were comparable to the rates of 20% and 5%,
espectively, found in a cross-sectional study with a sample
f HIV-infected individuals. In both studies, a high risk of sar-
openia in infected individuals was evident.11
Recently, Rees et al. reported a prevalence of frailty of 19%
n 122 HIV-infected patients evaluated using the 5-component
ried frailty criteria. The most common criteria were depres-
ion and low physical activity. Curiously, the least common
ere the markers of sarcopenia, leading the authors to con-
lude that frailty in HIV-infected individuals is potentially
eversible.14 Önen et al. evaluated a larger group of 445 HIV-
nfected patients with a mean age of 41.7 years and reported
 prevalence of frailty of 9%, which was associated with
omorbidities and more  advanced immunodeﬁciency.15 The
ntroduction of ART was found to exert a protective effect
gainst frailty in the follow-up of the Multicenter AIDS Cohort
tudy in the United States.16Wasserman et al. also reported a high prevalence of low
uscle mass (between 18.8 and 21.9% depending on the def-
nition used) in midlife and older HIV-infected individuals,
articularly males, despite CD4 cell reconstitution and viral 1 0.01
5.20 (1.40–19.20)
suppression.11 Several investigators have shown that HIV-
infected patients experience a loss of bone mass and have a
greater risk of fragility fractures.6,17 Until recently, the princi-
pal focus has been on preventing and managing bone disease
in HIV/AIDS.18 Nevertheless, muscle mass loss has begun to
attract the attention of healthcare providers, and there may
be a correlation with bone mass loss. This may constitute one
more  risk factor for patients with HIV/AIDS.19
There are some clear limitations associated with the
present study, particularly with reference to the small sam-
ple size and the consequent lack of statistical power to detect
differences when comparing the frequency of sarcopenia
between males and females or the loss of muscle mass with
the use of different antiretroviral drugs. Nevertheless, the
present results show a positive association of sarcopenia in
HIV-infected individuals. This association remained positive
even when compared with an older group and after control-
ling for the effect of age and BMI, thus constituting one more
component in the risk of falls and fractures in the aging HIV-
infected population.
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